SCHEMBL21274856

SCHEMBL21274856

CC(C)(C)OC(=O)N1[C@H](CCN)CCC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ DDB1 Q16531 2/20 0.33
▸ CRBN Q96SW2 2/20 0.33
▸ SPHK1 Q9NYA1 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ NR1H2 P55055 1/20 0.33
▸ HPGD P15428 1/20 0.32
▸ DPP4 P27487 1/20 0.32
▸ KDM1A O60341 1/20 0.31
▸ BUB1 O43683 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ GPR119 Q8TDV5 2/20 0.31
▸ RECQL P46063 1/20 0.31
▸ EPHX1 P07099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21244551 1.00 CHRM2 (0.35) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL21245137 0.92 SPHK1 (0.34) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL21275014 0.92 SPHK1 (0.34) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL21274727 0.91 SPHK1 (0.34) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL21244975 0.91 SPHK1 (0.34) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL21275009 0.88 CHRM2 (0.36) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL14239075 0.88 CHRM2 (0.36) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL31421605 0.86 CHRM2 (0.35) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL31420833 0.86 CHRM2 (0.35) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL21244705 0.84 SPHK1 (0.35) CHRM2CHRM1CHRM3DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752510-A1 MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM Vertex Pharmaceuticals Incorporated (US) 2020-12-23 — — EP disclosed
WO-2019161078-A1 MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-08-22 — — WO disclosed
Send feedback